Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 37 of 41.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next»
    EudraCT Number: 2009-009194-99 Sponsor Protocol Number: 2008002 Start Date*: 2009-07-15
    Sponsor Name:Agensys Inc
    Full Title: A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects with Metastatic Pancreatic Cancer ?Estudio global, multicéntrico, abierto, de fase ...
    Medical condition: Metastatic Pancreatic Cancer. To evaluate AGS-1C4D4 administered in combination with gemcitabine as measured by the survival rate at 6 months post-randomization Cancer de páncreas metástasico. Eva...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000417-36 Sponsor Protocol Number: DART01/05 Start Date*: 2005-05-31
    Sponsor Name:Dra. Almudena Zapatero Laborda
    Full Title: "PHASE III RANDOMISED AND MULTICENTRE TRIAL OF ADJUVANT ANDROGEN DEPRIVATION COMBINED WITH HIGH-DOSE THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY IN INTERMEDIATE-OR HIGH-RISK LOCALIZED PROSTATE CANCER"...
    Medical condition: Cáncer de Próstata localizado
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005518-11 Sponsor Protocol Number: 2006-10 Start Date*: 2007-01-24
    Sponsor Name:Örebro University Hospital
    Full Title: Epidural analgesia or opatient controlled regional analgesia for radical Retropubic Prostatectomy. A randomized, double-blind study.
    Medical condition: Postoperative pain after radical retropubic prostatectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002082-13 Sponsor Protocol Number: BUF-17/RAP Start Date*: 2008-07-09
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Randomised, double-blind, placebo-controlled, multicentre, comparative phase II pilot study on the efficacy and tolerability of an 8-week rectal treatment with 2 mg budesonide or placebo for the pr...
    Medical condition: prevention of acute radiation proctitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037766 Radiation proctitis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023957-12 Sponsor Protocol Number: RAPIDO Start Date*: 2011-03-29
    Sponsor Name:Dutch Colorectal Cancer Group [...]
    1. Dutch Colorectal Cancer Group
    2.
    Full Title: Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemor...
    Medical condition: primary rectal cancer without detectable distant metastasis, but with a high risk to relapse locally or systemically.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10038038 Rectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) NL (Ongoing) ES (Ongoing) SI (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000324-29 Sponsor Protocol Number: CA011-001 Start Date*: 2016-09-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors
    Medical condition: Serious ovarian cancer with wild-type BRCA1/2, triple negative breast cancer and small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000415-23 Sponsor Protocol Number: PM14-A-002-20 Start Date*: 2021-05-25
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001509-33 Sponsor Protocol Number: B9991025 Start Date*: 2018-05-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH ...
    Medical condition: Locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hormone receptor-positive (HR+) / human epide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065147 Malignant solid tumor LLT
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-011850-17 Sponsor Protocol Number: H6D-EW-LVIK Start Date*: 2009-10-23
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for...
    Medical condition: Erectile dysfunction following Bilateral Nerve-Sparing Radical Prostatectomy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10050756 Radical prostatectomy LLT
    12.0 10061461 Erectile dysfunction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) BE (Completed) GB (Completed) IT (Completed) PT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005460-28 Sponsor Protocol Number: CRAD001L2401 Start Date*: 2008-07-18
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor...
    Medical condition: Pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) AT (Completed) SK (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002243-42 Sponsor Protocol Number: GCT1021-01 Start Date*: 2016-10-25
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors.
    Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014742 Endometrial neoplasms malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-000087-16 Sponsor Protocol Number: CA182-026 Start Date*: 2009-03-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Lette...
    Medical condition: Subjects with Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001111-12 Sponsor Protocol Number: 1367.1 Start Date*: 2015-06-12
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit
    Medical condition: Advanced, unresectable and/or metastatic solid tumours, which have failed with conventional treatment or for which no therapy of proven efficacy exists, or in patients who are not amenable to stand...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012820 Diffuse large B-cell lymphoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010029 Colorectal cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078295 NUT midline carcinoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003085-12 Sponsor Protocol Number: ANT-008 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding i...
    Medical condition: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000314-38 Sponsor Protocol Number: 1206-HNCG Start Date*: 2014-07-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre...
    Medical condition: Salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011498-34 Sponsor Protocol Number: TAS 2009 Start Date*: 2009-10-22
    Sponsor Name:Ergomed Clinical Research Limited
    Full Title: An Open-Label, Multi-Center Phase I/II Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Advanced Solid Tumors (part A), and ...
    Medical condition: Solid tumours and metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065143 Malignant solid tumour LLT
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006277-24 Sponsor Protocol Number: EFC6145 Start Date*: 2008-04-10
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LI...
    Medical condition: Critical Limb Ischemia with skin lesions
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) CZ (Completed) GR (Completed) ES (Completed) AT (Completed) FI (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003025-18 Sponsor Protocol Number: VAPER Start Date*: 2015-05-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: In Vivo Generation of Optimal Tumour Antigen-specific Anticancer Immune Responses, by Vaccination with Human Telomerase Reverse Transcriptase (hTERT) Peptides, in Combination with Specific Adjuvant...
    Medical condition: Advanced malignancies
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000456-19 Sponsor Protocol Number: BC-09501 Start Date*: 2021-11-17
    Sponsor Name:University Hospital Ghent
    Full Title: Use of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers
    Medical condition: Patients with a iodine refractory thyroid carcinoma, who received an 18F -FDG PET/CT scan in routine clinical practice.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002119-28 Sponsor Protocol Number: BH 20198 Start Date*: 2006-07-17
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (Epoetin beta) therapy versus thrice weekly NeoRecorm...
    Medical condition: Anaemia in breast tumour subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) EE (Completed) DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) LV (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 16:01:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA